Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ImaginAb, Inc.
IAB2M is an approximately 80 kDA molecular weight antibody fragment (a "Minibody"). Limited (Phase 0/Proof-of-concept) patient experience with this biologic targeting agent has been previously obtained with SPECT imaging Ex-US, demonstrating targeting of soft tissue and bone lesions in advanced metastatic prostate cancer.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adult male \>/= 18 years of age
Patients with histologically confirmed prostate cancer
Progressive disease manifest (within 6 weeks of screening) by either
* imaging modalities (bone scan, MRI or CT) OR
* biochemical progression (PSA)
Performance status of 60 or higher on Karnofsky scale
Subject's schedule permits compliance with all study procedures
Ability to understand and willingness to sign a written informed consent form
You may not be if
Previous anaphylactic reaction to huJ591 antibody or FDG imaging
On any new anticancer therapy (GnRH analog allowed) while on the study
Other severe acute or chronic medical condition that may increase the risk associated with study participation or investigational product administration
Clareo Health | Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer
